A TLR7/8 agonist–chitosan conjugate as an adjuvant for carbohydrate-based anticancer vaccine development
Abstract
The TLR7/8 agonist imidazoquinoline (IMDQ), 1-(4-(amino-methyl)benzyl)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-4-amine, conjugated to chitosan was found to be a superior adjuvant to aluminum salts for vaccination against tumor-associated carbohydrate antigens.